Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.36 |
| ▸ | GCGR | P47871 | 4/20 | 0.35 |
| ▸ | GIPR | P48546 | 3/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2361799 | 0.84 | DDB1 (0.41) | PDE3BPDE3ATRPM8 | |
| SCHEMBL2284752 | 0.81 | RIPK1 (0.43) | — | |
| SCHEMBL2283134 | 0.81 | RIPK1 (0.43) | — | |
| SCHEMBL2283000 | 0.80 | KIF11 (0.38) | KIF11PDE3BPDE3A | |
| SCHEMBL2279613 | 0.80 | KIF11 (0.38) | KIF11PDE3BPDE3A | |
| SCHEMBL17312580 | 0.79 | RIPK1 (0.44) | MAPTSMN1; SMN2PPARDPPARALRRK2 | |
| SCHEMBL17312581 | 0.79 | RIPK1 (0.44) | MAPTSMN1; SMN2PPARDPPARALRRK2 | |
| SCHEMBL2281716 | 0.79 | PYGL (0.43) | MAPT | |
| SCHEMBL2283972 | 0.79 | PYGL (0.43) | MAPT | |
| SCHEMBL17312604 | 0.76 | OPRM1 (0.35) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212891-A1 | AZEPINONE DERIVATIVES | MSD K.K. | 2011-09-01 | — | — | US | disclosed |
| EP-2358735-A1 | AZEPINONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010056496-A1 | AZEPINONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212891-A1 | AZEPINONE DERIVATIVES | AZI2, NDUFS3, RPS4Y1 | MAPT 4687/4885SMN1; SMN2 4372/4885CES1 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.